Product Information
TRIAZOLAM 0.25 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.3084 per EA under NDC 59762371803. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 15, 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.25 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762371803
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TRIAZOLAMApproval Type
Authorized Generic (NDA)
FDA Application
NDA017892FDA Approved
11/15/1982
TE Code
AB
On Market Since
11/15/1982
Pharmacological Classes
Price Statistics
The NADAC for TRIAZOLAM 0.25 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 51.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3084 per EA |
|---|---|
| All-time high | $1.6632 (Mar 14, 2018) |
| All-time low | $0.2380 (Nov 20, 2024) |
| 52-week high | $0.3691 |
| 52-week low | $0.3011 |
| Median price | $1.0955 |
| Average price | $0.9899 |
| Largest weekly change | +51.7% (May 22, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
triazolam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIAZOLAM 0.25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRIAZOLAM 0.25 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.3084 per EA (NDC 59762371803), effective Sep 30, 2026.
How has the price of TRIAZOLAM 0.25 MG TABLET changed over time?
Over the history we have for it, the NADAC for TRIAZOLAM 0.25 MG TABLET has declined 51.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRIAZOLAM 0.25 MG TABLET?
Since Nov 28, 2013, the NADAC for TRIAZOLAM 0.25 MG TABLET has ranged from a low of $0.2380 (Nov 20, 2024) to a high of $1.6632 (Mar 14, 2018), with a median of $1.0955 per EA.
Are there cheaper alternatives to TRIAZOLAM 0.25 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TRIAZOLAM 0.25 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TRIAZOLAM 0.25 MG TABLET?
TRIAZOLAM 0.25 MG TABLET (NDC 59762371803) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.